4985. Insulin Glulisine

Nomenclature

CAS number: 207748-29-6
3B-l-Lysine-29B-l-glutamic acid-insulin (human); [Lys(B3),Glu(B29)]-insulin (human); HMR-1964; Apidra (Sanofi-Aventis).
C258H384N64O78S6; mol wt 5822.58.
C 53.22%, H 6.65%, N 15.40%, O 21.43%, S 3.30%.

Description and references

Rapid-acting insulin analog produced in E. coli by recombinant DNA technology. Identical to human insulin except for 2 amino acid substitutions. Prepn: J. Ertl et al., EP 885961 (1998 to Hoechst Marion Roussel); eidem, US 6221633 (2001 to Aventis). Evaluation of mitogenic potential: I. Rakatzi et al., Diabetes 52, 2227 (2003); of β-cell protective effect: idem et al., Biochem. Biophys. Res. Commun. 310, 852 (2003). Clinical trial in type 2 diabetes: G. Dailey et al., Diabetes Care 27, 2363 (2004). Review: S. K. Garg et al., Expert Opin. Pharmacother. 6, 643-651 (2005).

Therapeutic Category

Antidiabetic.

Keywords

Antidiabetic; Hormones/Analogs